Schedule 13D ownership disclosure
Summit Therapeutics plc
Security class unavailable · CUSIP: 86627R102
Event date: 2020-05-08
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 5.2600%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-20-003557
- Form type
- SC 13D
- Filer
- LANSDOWNE PARTNERS
- CIK
- CIK 1608485
- Filed
- May 15, 2020
- Reporting period
- May 08, 2020
- Description
- Schedule 13D beneficial ownership